# John M. Kirkwood

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/john-m-kirkwood/

## Facts

| Field | Value |
| --- | --- |
| Citations | 93,361 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 138 |
| i10-index | 583 |
| Last Known Institution | University of Malawi |
| OpenAlex ID | https://openalex.org/A5007239425 |
| ORCID iD | https://orcid.org/0000-0002-3570-4476 |
| Works | 1,380 |

## Researcher papers

Showing 12 of 14.

- [Final Version of 2009 AJCC Melanoma Staging and Classification](https://scholariq.org/papers/final-version-of-2009-ajcc-melanoma-staging-and-classification/)
- [Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma](https://scholariq.org/papers/final-version-of-the-american-joint-committee-on-cancer-staging-system-for/)
- [Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System](https://scholariq.org/papers/prognostic-factors-analysis-of-17-600-melanoma-patients-validation-of-the/)
- [High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190](https://scholariq.org/papers/high-and-low-dose-interferon-alfa-2b-in-high-risk-melanoma-first-analysis-of/)
- [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/overall-survival-benefit-with-tebentafusp-in-metastatic-uveal-melanoma/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials](https://scholariq.org/papers/meta-analysis-of-phase-ii-cooperative-group-trials-in-metastatic-stage-iv/)
- [Development of Metastatic Disease After Enrollment in the COMS Trials for Treatment of Choroidal Melanoma](https://scholariq.org/papers/development-of-metastatic-disease-after-enrollment-in-the-coms-trials-for/)
- [A new American Joint Committee on Cancer staging system for cutaneous melanoma](https://scholariq.org/papers/a-new-american-joint-committee-on-cancer-staging-system-for-cutaneous-melanoma/)
- [Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases](https://scholariq.org/papers/multivariate-analysis-of-prognostic-factors-among-2-313-patients-with-stage-iii/)
- [Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study](https://scholariq.org/papers/efficacy-and-safety-of-lifileucel-a-one-time-autologous-tumor-infiltrating/)
- [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://scholariq.org/papers/three-year-overall-survival-with-tebentafusp-in-metastatic-uveal-melanoma/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [University of Malawi](https://scholariq.org/institutions/university-of-malawi/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.